1,926 Shares in Novartis AG (NYSE:NVS) Bought by Hummer Financial Advisory Services Inc

Hummer Financial Advisory Services Inc bought a new stake in Novartis AG (NYSE:NVS) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,926 shares of the company’s stock, valued at approximately $205,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVS. NBC Securities Inc. grew its stake in Novartis by 0.9% during the 2nd quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock worth $1,116,000 after buying an additional 97 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Novartis by 5.1% during the first quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock valued at $196,000 after acquiring an additional 98 shares in the last quarter. Evermay Wealth Management LLC raised its position in shares of Novartis by 9.3% in the 1st quarter. Evermay Wealth Management LLC now owns 1,176 shares of the company’s stock valued at $114,000 after purchasing an additional 100 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in Novartis by 1.5% in the 1st quarter. Rehmann Capital Advisory Group now owns 7,043 shares of the company’s stock worth $681,000 after purchasing an additional 103 shares in the last quarter. Finally, Davidson Trust Co. grew its position in Novartis by 1.4% during the 4th quarter. Davidson Trust Co. now owns 7,864 shares of the company’s stock worth $794,000 after purchasing an additional 112 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. The Goldman Sachs Group started coverage on Novartis in a research report on Thursday, May 30th. They issued a “buy” rating and a $120.00 target price on the stock. Barclays raised Novartis to a “strong sell” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Novartis in a report on Friday, July 19th. Jefferies Financial Group lifted their price objective on shares of Novartis from $121.00 to $122.50 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Finally, BMO Capital Markets raised their target price on shares of Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $118.13.

Novartis Stock Performance

Shares of NYSE:NVS traded up $0.87 during trading on Friday, hitting $111.89. 1,037,513 shares of the stock traded hands, compared to its average volume of 1,516,447. The company has a fifty day moving average price of $108.00 and a two-hundred day moving average price of $102.57. Novartis AG has a 52-week low of $92.19 and a 52-week high of $113.00. The company has a market cap of $228.70 billion, a price-to-earnings ratio of 15.10, a P/E/G ratio of 1.62 and a beta of 0.57. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.10. The business had revenue of $12.87 billion during the quarter, compared to the consensus estimate of $12.24 billion. Novartis had a net margin of 33.76% and a return on equity of 34.56%. During the same quarter in the prior year, the firm posted $1.83 earnings per share. As a group, equities analysts predict that Novartis AG will post 7.41 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.